Revolution Medicines Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Mark Goldsmith

İcra Kurulu Başkanı

US$10.4m

Toplam tazminat

CEO maaş yüzdesi	6.1%
CEO görev süresi	10yrs
CEO sahipliği	0.4%
Yönetim ortalama görev süresi	6.5yrs
Yönetim Kurulu ortalama görev süresi	7.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Mark Goldsmith'un ücretlendirmesi Revolution Medicines'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$567m
Jun 30 2024	n/a	n/a	-US$519m
Mar 31 2024	n/a	n/a	-US$484m
Dec 31 2023	US$10m	US$631k	-US$436m
Sep 30 2023	n/a	n/a	-US$331m
Jun 30 2023	n/a	n/a	-US$296m
Mar 31 2023	n/a	n/a	-US$259m
Dec 31 2022	US$7m	US$607k	-US$249m
Sep 30 2022	n/a	n/a	-US$245m
Jun 30 2022	n/a	n/a	-US$224m
Mar 31 2022	n/a	n/a	-US$208m
Dec 31 2021	US$8m	US$581k	-US$187m
Sep 30 2021	n/a	n/a	-US$169m
Jun 30 2021	n/a	n/a	-US$143m
Mar 31 2021	n/a	n/a	-US$126m
Dec 31 2020	US$2m	US$554k	-US$110m
Sep 30 2020	n/a	n/a	-US$95m
Jun 30 2020	n/a	n/a	-US$85m
Mar 31 2020	n/a	n/a	-US$71m
Dec 31 2019	US$5m	US$504k	-US$62m
Sep 30 2019	n/a	n/a	-US$57m
Dec 31 2018	US$1m	US$490k	-US$49m

Tazminat ve Piyasa: Mark 'nin toplam tazminatı ($USD 10.41M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.59M ).

Tazminat ve Kazançlar: Mark şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Mark Goldsmith (62 yo)

10yrs

Görev süresi

US$10,411,247

Tazminat

Dr. Mark A. Goldsmith, M.D., Ph.D. is the Chief Executive Officer, President and Director of Revolution Medicines, Inc. since November 2014 and serves as its Chairman. Dr. Goldsmith served as a Venture Par...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mark Goldsmith	CEO, President & Chairman	10yrs	US$10.41m	0.39% € 35.7m
Jack Anders	Chief Financial Officer	6.3yrs	US$3.05m	0.029% € 2.7m
Margaret Horn	Chief Operating Officer	6.1yrs	US$4.39m	0.033% € 3.0m
Stephen Kelsey	President of Research & Development	7.7yrs	US$4.39m	0.11% € 9.7m
Xiaolin Wang	Executive Vice President of Development	6.7yrs	US$3.23m	0.015% € 1.4m
Martin Burke	Co-Founder & Chairman of Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Fischbach	Academic Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Kevan Shokat	Academic Co-Founder & Member of Scientific Advisory Board	7.9yrs	Veri yok	Veri yok
Walter Reiher	Chief Information Officer	no data	Veri yok	Veri yok
Jan Smith	Chief Scientific Officer	1.3yrs	Veri yok	Veri yok
Erin Graves	Senior Director of Corporate Communications & Investor Relations	no data	Veri yok	Veri yok
Jeff Cislini	Senior VP	2.2yrs	Veri yok	0.0017% € 156.8k

6.5yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: 42Z 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mark Goldsmith	CEO, President & Chairman	10yrs	US$10.41m	0.39% € 35.7m
Martin Burke	Co-Founder & Chairman of Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Fischbach	Academic Co-Founder & Member of Scientific Advisory Board	8.4yrs	Veri yok	Veri yok
Kevan Shokat	Academic Co-Founder & Member of Scientific Advisory Board	7.9yrs	Veri yok	Veri yok
Julian Adams	Senior Advisor & Member of Scientific Advisory Board	7.9yrs	Veri yok	Veri yok
Alexis Borisy	Lead Independent Director	10yrs	US$510.63k	1.39% € 127.1m
Eric Gordon	Senior Advisor & Member of Scientific Advisory Board	8.4yrs	Veri yok	Veri yok
John Kuriyan	Senior Advisor & Member of Scientific Advisory Board	7.9yrs	Veri yok	Veri yok
Lorence Kim	Independent Director	2.3yrs	US$489.99k	0.036% € 3.3m
Thilo Schroeder	Independent Director	6.7yrs	Veri yok	Veri yok
Elizabeth Anderson	Independent Director	9.7yrs	US$483.78k	0.025% € 2.3m
Trever Bivona	Senior Advisor & Member of Scientific Advisory Board	7.9yrs	Veri yok	Veri yok

7.9yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 42Z 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.9 yıldır).

Revolution Medicines Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

CEO, President & Chairman recently sold €507k worth of stock

Revolution Medicines, Inc., Annual General Meeting, Jun 20, 2024

Revolution Medicines, Inc. Resigns Eric T. Schmidt as Board of Directors

Revolution Medicines, Inc. Announces Executives Appointment

Revolution Medicines, Inc. Announces Executive Changes

Revolution Medicines, Inc. Appoints Lorence Kim to Board of Directors

Recent updates

CEO, President & Chairman recently sold €507k worth of stock

Revolution Medicines, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Now 22% undervalued

Now 20% undervalued

New major risk - Revenue size

Revolution Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Revolution Medicines, Inc. to Report Q2, 2024 Results on Aug 07, 2024

New major risk - Revenue and earnings growth

Revolution Medicines, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024

Revolution Medicines, Inc. Announces Publication Demonstrating Robust Anti-Tumor Activity of Ras(On) Inhibitors in Preclinical Models of Refractory Kras-Mutated Non-Small Cell Lung Cancer

Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.70 loss per share (vs US$0.72 loss in 1Q 2023)

Revolution Medicines, Inc. to Report Q1, 2024 Results on May 08, 2024

Revolution Medicines, Inc., Annual General Meeting, Jun 20, 2024

Revolution Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $124.825544 million.

Revolution Medicines, Inc. Provides Earnings Guidance for Full Year 2024

Full year 2023 earnings released: US$3.86 loss per share (vs US$3.09 loss in FY 2022)

New major risk - Revenue and earnings growth

Revolution Medicines, Inc. to Report Q4, 2023 Results on Feb 26, 2024

New major risk - Shareholder dilution

Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

Third quarter 2023 earnings released: US$0.99 loss per share (vs US$0.87 loss in 3Q 2022)

Revolution Medicines, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Revolution Medicines, Inc. Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236

New major risk - Revenue and earnings growth

New major risk - Share price stability

Revolution Medicines, Inc. Provides Pipeline Updates

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

Revolution Medicines, Inc. Resigns Eric T. Schmidt as Board of Directors

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$0.82 loss in 2Q 2022)

Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2023

Revolution Medicines, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Revolution Medicines, Inc. (NasdaqGS:RVMD) entered into a definitive agreement to acquire EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

Revolution Medicines, Inc.(NasdaqGS:RVMD) dropped from Russell Small Cap Comp Value Index

First quarter 2023 earnings released: US$0.72 loss per share (vs US$0.78 loss in 1Q 2022)

Revolution Medicines, Inc. Announces Executives Appointment

Full year 2022 earnings released: US$3.09 loss per share (vs US$2.57 loss in FY 2021)

Revolution Medicines, Inc. Announces Publication Describing Design and Synthesis of RMC-5552

Revolution Medicines, Inc. to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration

Revolution Medicines, Inc. Updates Earnings Guidance for 2022

Third quarter 2022 earnings released: US$0.87 loss per share (vs US$0.72 loss in 3Q 2021)

Revolution Medicines, Inc. Provides Earnings Guidance for the Full Year 2022

Revolution Medicines, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

Revolution Medicines, Inc. Announces Executive Changes

Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.60 loss in 2Q 2021)

Revolution Medicines, Inc. Provides Earnings Guidance for the Year 2022

Revolution Medicines, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Revolution Medicines, Inc. Appoints Lorence Kim to Board of Directors

Revolution Medicines, Inc. Elects Sushil Patel to its Board of Directors

Revolution Medicines, Inc. Appoints Sushil Patel, Ph.D. as Director

First quarter 2022 earnings released: US$0.78 loss per share (vs US$0.53 loss in 1Q 2021)

Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2022

Revolution Medicines, Inc. to Report Q1, 2022 Results on May 09, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Revolution Medicines, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Revolution Medicines, Inc. Provides Earnings Guidance for the Year Ended December 31, 2021

Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference

Third quarter 2021 earnings released: US$0.72 loss per share (vs US$0.42 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.60 loss per share (vs US$0.46 loss in 2Q 2020)

Revolution Medicines, Inc. Provides Earnings Guidance for the Full Year 2021

Revolution Medicines, Inc. Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1

Independent Director Peter Svennilson has left the company

Revolution Medicines, Inc. Provides Earnings Guidance for Full Year 2021

First quarter 2021 earnings released: US$0.53 loss per share (vs US$0.74 loss in 1Q 2020)

Full year 2020 earnings released: US$2.01 loss per share (vs US$22.33 loss in FY 2019)

Revenue misses expectations

New 90-day high: €37.80